Talk:Oligomycin
From Bioblast
Revision as of 00:15, 22 February 2013 by Gnaiger Erich (talk | contribs) (Created page with "== ETS capacity after inhibition by Omy == * We are having problems recovering full activity with FCCP after oligomycin, and although diluting Omy to low but effective concentra...")
ETS capacity after inhibition by Omy
- We are having problems recovering full activity with FCCP after oligomycin, and although diluting Omy to low but effective concentration help, it does not solve the problem. Thus, we are considering buying the more expensive forms of Omy. (2013-02-21; Doug Crawford, University of Miami, US)
- We are facing the same problems during recent years, and are worried about what is going wrong. Whereas pathologically stressed mitos with a latent injury do respond to the additional Omy induced stress by loosing ETS capacity, the controls gave us recently the same problems, which we consider as artefacts for unknown reasons. Quality control of formerly functional chemicals becomes an increasingly worrying issue. (2013-02-21; Erich Gnaiger, Medical University Innsbruck, AT)
